ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Efficacy and Tolerability of Tedizolid Phosphate in the Treatment of Mycobacterium Abscessus Infection among Pediatric Hematopoietic Stem Cell Transplant Recipients

Y. Kang, V. M. Aquino, A. Y. Koh, D. Wetzel, P. K. Sue

Pediatrics, UT Southwestern Medical Center, Dallas, TX

Meeting: 2020 American Transplant Congress

Abstract number: B-184

Keywords: Bacterial infection, Bone marrow transplantation, Infection, Pediatric

Session Information

Session Name: Poster Session B: All Infections (Excluding Kidney & Viral Hepatitis)

Session Type: Poster Session

Date: Saturday, May 30, 2020

Session Time: 3:15pm-4:00pm

 Presentation Time: 3:30pm-4:00pm

Location: Virtual

*Purpose: Mycobacterium abscessus complex infections are associated with high rates of morbidity and mortality in immunocompromised hosts. Treatment can be challenging due to broad spectrum antimicrobial resistance that often requires prolonged and frequently toxic therapeutic regimens. Further, HSCT recipients are at increased risk for complications associated with prolonged parenteral and myelosuppressive antibiotic regimens. Tedizolid phosphate is an oral oxazolidinone with demonstrated efficacy against M. abscessus, and may be a safe treatment option in patients requiring prolonged therapy. We report two cases of M. abscessus infection in pediatric HSCT recipients treated with oral tedizolid phosphate.

*Methods: Patient 1, a 16 yo F with a history of relapsed Acute Lymphoblastic Leukemia (ALL) presented with erythema, exudate, and induration of a central venous line site on day + 15 following allogeneic HSCT. Blood and wound cultures were positive for M.abscessus and susceptibility testing demonstrated in vitro resistance to moxifloxacin, ciprofloxacin, doxycycline, minocycline, with intermediate susceptibility to cefoxitin and imipenem, and sensitivity to clarithromycin, linezolid and amikacin. Patient 2, a 14 yo M with relapsed ALL presented with fever and exudative skin and soft tissue infection with associated M. abscessus bacteremia on day +8 following allogeneic HSCT. Susceptibility testing of the isolate demonstrated in vitro resistance to moxifloxacin, ciprofloxacin and doxycycline, intermediate susceptibility to cefoxitin, minocycline and imipenem, and susceptibility to linezolid, amikacin, and clarithromycin.

*Results: Treatment induction regimens for both patients consisted imipenem, azithromycin and amikacin, with durations of 4 and 6 weeks, respectively. Patient WBC, Hgb, and platelet counts following induction were within anticipated range. In both patients, there was resolution of fevers, and clearance of bacteremia (days 2 and 5) with adequate source control. Continuation phase therapy consisted of oral tedizolid phosphate and azithromycin for an additional 16 and 12 weeks, respectively with no evidence of progression or rebound infection at 3 and 2 months respectively.

*Conclusions: Tedizolid phosphate is a novel oxazolidinone with demonstrated activity against M. abscessus and a favorable toxicity profile. We report the first 2 cases to our knowledge, of M. abscessus infection successfully treated with an oral tedizolid phosphate containing antimicrobial regimen in pediatric HSCT recipients. Incorporation of this agent into treatment regimens for M. abscessus infection may decrease superfluous parenteral and toxic antibiotic exposures among high risk HSCT recipients.

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Kang Y, Aquino VM, Koh AY, Wetzel D, Sue PK. Efficacy and Tolerability of Tedizolid Phosphate in the Treatment of Mycobacterium Abscessus Infection among Pediatric Hematopoietic Stem Cell Transplant Recipients [abstract]. Am J Transplant. 2020; 20 (suppl 3). https://atcmeetingabstracts.com/abstract/efficacy-and-tolerability-of-tedizolid-phosphate-in-the-treatment-of-mycobacterium-abscessus-infection-among-pediatric-hematopoietic-stem-cell-transplant-recipients/. Accessed May 10, 2025.

« Back to 2020 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences